文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

溃疡性结肠炎的疾病清除:为溃疡性结肠炎未来的治疗设定治疗目标。

Disease clearance in ulcerative colitis: Setting the therapeutic goals for future in the treatment of ulcerative colitis.

作者信息

Ramos Laura, Teo-Loy Jeny, Barreiro-de Acosta Manuel

机构信息

IBD Unit, Department of Gastroenterology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.

Department of Internal Medicine, University of La Laguna, Santa Cruz de Tenerife, Spain.

出版信息

Front Med (Lausanne). 2023 Jan 9;9:1102420. doi: 10.3389/fmed.2022.1102420. eCollection 2022.


DOI:10.3389/fmed.2022.1102420
PMID:36698823
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9868775/
Abstract

Ulcerative colitis, one of the phenotypic patterns of inflammatory bowel disease, should be considered a progressive disease with an increased risk of complications if intestinal inflammation is not adequately controlled. The advent of new lines of treatment for this condition has changed and expanded the therapeutic goals to modify its natural history and evolution. The concept of "disease clearance" in ulcerative colitis aims to achieve clinical and biological remission as well as mucosal healing (endoscopic, histological, and in future molecular) in these patients. This review provides the available data on each of the goals of disease clearance in ulcerative colitis to be considered for application in clinical practice in the coming years.

摘要

溃疡性结肠炎是炎症性肠病的一种表型模式,如果肠道炎症得不到充分控制,应被视为一种有并发症风险增加的进展性疾病。针对这种疾病的新治疗方法的出现改变并扩展了治疗目标,以改变其自然病史和病程。溃疡性结肠炎中“疾病清除”的概念旨在使这些患者实现临床和生物学缓解以及黏膜愈合(内镜、组织学以及未来的分子层面)。本综述提供了关于溃疡性结肠炎疾病清除各项目标的现有数据,以供未来几年在临床实践中应用时参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a7e/9868775/56e81cd627a9/fmed-09-1102420-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a7e/9868775/56e81cd627a9/fmed-09-1102420-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a7e/9868775/56e81cd627a9/fmed-09-1102420-g001.jpg

相似文献

[1]
Disease clearance in ulcerative colitis: Setting the therapeutic goals for future in the treatment of ulcerative colitis.

Front Med (Lausanne). 2023-1-9

[2]
Disease clearance in ulcerative colitis: A new therapeutic target for the future.

World J Gastroenterol. 2024-4-7

[3]
Current and Emerging Targeted Therapies for Ulcerative Colitis.

Visc Med. 2023-6

[4]
Which evidence for a treat to target strategy in ulcerative colitis?

Best Pract Res Clin Gastroenterol. 2018-5-12

[5]
Definition and evaluation of mucosal healing in clinical practice.

Dig Liver Dis. 2013-8-7

[6]
Is histological healing a feasible endpoint in ulcerative colitis?

Expert Rev Gastroenterol Hepatol. 2021-6

[7]
Treat to target in inflammatory bowel disease: a survey of treatment strategies amongst Portuguese doctors.

Rev Esp Enferm Dig. 2019-8

[8]
Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, quality-of-life and economic outcomes.

Curr Med Res Opin. 2022-9

[9]
Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative.

J Crohns Colitis. 2014-12

[10]
[New therapeutic goals in inflammatory bowel diseases].

Rev Prat. 2014-11

引用本文的文献

[1]
Enrichment of short-chain fatty acid-producing bacteria by pH-responsive sodium alginate and chitosan-encapsulated quercetin.

Front Microbiol. 2025-8-6

[2]
makino alleviates ulcerative colitis in mice by modulating the Nrf2/Keap1 pathway.

Front Pharmacol. 2025-4-28

[3]
Disease Clearance in Ulcerative Colitis: A Narrative Review.

United European Gastroenterol J. 2025-7

[4]
Dose Escalation Patterns and Associated Costs of Advanced Therapies for Ulcerative Colitis in France and the United Kingdom: A Retrospective Database Analysis.

Clinicoecon Outcomes Res. 2025-3-1

[5]
Advancing Therapeutic Targets in IBD: Emerging Goals and Precision Medicine Approaches.

Pharmaceuticals (Basel). 2025-1-10

[6]
Thermosensitive and pH-responsive quercus infectoria gall-containing gel with long-lasting anti-inflammatory activity for ulcerative colitis.

Heliyon. 2024-8-13

[7]
Managing Ulcerative Colitis and Crohn's Disease: Should the Target Be Endoscopy, Histology, or Both?

J Can Assoc Gastroenterol. 2023-9-23

[8]
Evaluation of Disease Activity in Inflammatory Bowel Disease: Diagnostic Tools in the Assessment of Histological Healing.

Biomedicines. 2023-11-18

[9]
Oral Administration of Platinum Nanoparticles with SOD/CAT Cascade Catalytic Activity to Alleviate Ulcerative Colitis.

J Funct Biomater. 2023-11-15

[10]
Glycated Casein by TGase-Type Exerts Protection Potential against DSS-Induced Colitis via Inhibiting TLR4/NF-κB Signaling Pathways in C57BL/6J Mice.

Foods. 2023-9-14

本文引用的文献

[1]
Ulcerative colitis: Impact of early disease clearance on long-term outcomes - A multicenter cohort study.

United European Gastroenterol J. 2022-9

[2]
An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis.

J Clin Med. 2022-4-20

[3]
Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis.

BMC Gastroenterol. 2022-3-3

[4]
Assessment of Endoscopic Disease Activity in Ulcerative Colitis: Is Simplicity the Ultimate Sophistication?

Inflamm Intest Dis. 2021-8-18

[5]
What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented?

Gastroenterology. 2022-4

[6]
The Role of Innate and Adaptive Immune Cells in the Pathogenesis and Development of the Inflammatory Response in Ulcerative Colitis.

J Clin Med. 2022-1-13

[7]
Combined Histo-endoscopic Remission but not Endoscopic Healing Alone in Ulcerative Colitis is Associated with a Mucosal Transcriptional Profile Resembling Healthy Mucosa.

J Crohns Colitis. 2022-8-4

[8]
Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis.

Sci Rep. 2021-9-14

[9]
Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment.

Int J Environ Res Public Health. 2021-7-4

[10]
Increased mucosal IL-12 expression is associated with relapse of ulcerative colitis.

BMC Gastroenterol. 2021-3-17

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索